Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer

Salima Hamizi1 Department of Medical Oncology, Lyon 1 University and Hospices Civils de Lyon, Lyon, France

Gilles Freyer1 Department of Medical Oncology, Lyon 1 University and Hospices Civils de Lyon, Lyon, FranceCorrespondence[email protected]

Naoual Bakrin2 Department of Gynecologic Surgery, Centre Hospitalier Lyon-Sud, Lyon, France

Emilie Henin3 EMR 3738 Therapeutic Modeling in Oncology, Lyon 1 University, Lyon, France

Amina Mohtaram1 Department of Medical Oncology, Lyon 1 University and Hospices Civils de Lyon, Lyon, France

Olivia Le Saux1 Department of Medical Oncology, Lyon 1 University and Hospices Civils de Lyon, Lyon, France

Claire Falandry4 Department of Geronto-Oncology and Geriatrics, Centre Hospitalier Lyon-Sud, Lyon, France

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.